【高血压英文PPT精品课件】 Primary Care Today Educational Conference and Medical Exposition.ppt

下载文档 降价啦

6
0
约3.45万字
约 95页
2018-06-29 发布于浙江
举报
版权申诉
保障服务

【高血压英文PPT精品课件】 Primary Care Today Educational Conference and Medical Exposition.ppt

1、本文档共95页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

【高血压英文PPT精品课件】 Primary Care Today Educational Conference and Medical Exposition

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Approximately 1 in 5 patients with PAD will experience CV death, MI, stroke, or hospitalization within 1 year Breakdown of event rates PAD CAD CVD ????? ?????? ??????? 21.1% 1 in ~5 15.2% 1 in ~6 14.5% 1 in ~7 Steg PG et al, on behalf of the REACH Registry Investigators. JAMA 2007;297(11):1197-1206. Take-Home Messages Take-Home Messages (continued) ~ 60% of patients with PAD have diffuse vascular disease ~ 15% of patients with PAD will require a vascular intervention at 1 year Lifelong antiplatelet therapy with ASA or clopidogrel is recommended for patients with PAD Adherence to guideline recommendations may lead to reduced mortality in PAD * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Question 5 Which of the following in NOT appropriate Anti-platelet therapy for Louise? ER Dipyrdamole 200 mg plus ASA 25 mg BID ECASA 81 mg plus clopidogrel 75 mg OD ECASA 81 - 325 mg OD alone Clopidogrel 75 mg OD alone None of the above, all are reasonable ? MATCH: Results Cumulative Event Rate (Ischemic Stroke, MI, Vascular Death, Rehospitalization due to Ischemic Event) Months of follow-up 6.4% RRR 1.03% ARR P=0.244 0 6 12 18 0 1 3 6 12 18 Cumulative event rate (%) Placebo ASA On-Treatment Analysis: 9.6% RRR, 1.6% ARR, p=0.10 * All patients received clopidogrel background therapy Diener HC, et al. Lancet. 2004; 364:331-337. ESPS 2:Risk Reduction for Stroke or Death Stroke relative risk reduction (%) P0.001 P0.05 P0.05 P=0.006 ER DP = extended release dipyridamole n = 6602 within 3 months of stroke or TIA 2 years of follow-up Diener HC, et al. J Neurol Sci. 1996;143:1-13. Antithrombotic Trialists’ Collaboration ASA dose 500 – 1500 mg daily 160 – 325 mg daily 75 – 150 mg daily 75 mg daily Any ASA dose 0.0 0.5 1.0 1.5 ASA better Control better % odds reduction* Antithrombotic Trialists’ Collaboration. BMJ. 2002;324:71-86. 23% + 2 (P0.